Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial

Table 4

Definite, probable, and possible adverse reactions of study intervention by week 4.

	TJ-54 (n = 56)	Placebo (n = 62)
Psychological	0	1
Neurological	0	0
Gastrointestinal	0	1
Genitourinary	0	0
Musculoskeletal	0	0
Dermatological	0	0
Respiratory	0	0
Cardiovascular	0	0
Infection	0	0
Ear, nose, and throat	0	0
Haematological	0	1
Endocrine	0	2
Other	0	0
Overall	0	5

Data are number of participants (number of events). Participants could report more than one category of event.